Combination therapy with cryoablation and radiofrequency ablation for lung cancer

Combination therapy with cryoablation and radiofrequency ablation for lung cancer - Combination therapy with cryoablation and radiofrequency ablation for lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054072

Enrollment

500

Registered

2024-04-05

Start date

2024-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary lung cancer and metastatic lung cancer

Interventions

For lung cancer, after cryoablation, the cryoablation probe is replaced by radiofrequency probe, followed by cryoablation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Lung cancer larger than 2 cm. 2. Even for lung cancer less than 2 cm, metastatic lung cancer, primary lung cancer with high FDG-uptake on PET, and predicted resistance for freezing or heating. 3. Patient strongly requested the combination therapy with cryoablation and radiofrequency ablation.

Exclusion criteria

Exclusion criteria: 1. Severe pulmonary failure. 2. Life expectancy is predicted to be less than 6 months. 3. Active interstitial pneumonia.

Design outcomes

Primary

Measure	Time frame
Local control rate and survival rate more than 3 years after the treatment	—

Secondary

Measure	Time frame
Short- and long-term complications after treatment	—

Countries

Japan

Contacts

Public ContactHiroaki Nomori

Kashiwa Kousei General Hospital Department of thoracic surgery

hnomori@qk9.so-net.ne.jp0471451111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026